Charles Le. Vogel
#162,990
Most Influential Person Now
Charles Le. Vogel's AcademicInfluence.com Rankings
Charles Le. Vogelphilosophy Degrees
Philosophy
#9466
World Rank
#13030
Historical Rank
Logic
#6439
World Rank
#7956
Historical Rank

Download Badge
Philosophy
Charles Le. Vogel's Degrees
- PhD Biomedical Sciences University of California, San Francisco
- Doctorate Medicine Stanford University
Why Is Charles Le. Vogel Influential?
(Suggest an Edit or Addition)Charles Le. Vogel's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer (2002) (3080)
- Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. (1999) (2850)
- Aspergillosis. The spectrum of the disease in 98 patients. (1970) (958)
- Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. (1999) (782)
- Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. (2011) (645)
- Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. (1997) (559)
- Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. (2009) (511)
- Adjuvant docetaxel for node-positive breast cancer. (2005) (508)
- First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. (2005) (478)
- Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma (1998) (459)
- Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. (1996) (397)
- Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. (2003) (359)
- Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. (2005) (349)
- Liver cell dysplasia: a premalignant condition (1973) (300)
- Kaposi's sarcoma in Uganda: A clinico‐pathological study (1971) (292)
- Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. (2001) (262)
- Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. (2001) (222)
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer (2012) (221)
- Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. (1995) (218)
- First-Line Herceptin® Monotherapy in Metastatic Breast Cancer (2001) (207)
- A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma (1997) (206)
- HER2 testing in breast cancer: NCCN Task Force report and recommendations. (2006) (205)
- Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. (2013) (199)
- Secretion of methotrexate into human milk. (1972) (195)
- Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. (1995) (189)
- Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. (1995) (183)
- Hepatitis-associated antigen in Ugandan patients with hepatocellular carcinoma. (1970) (177)
- Final 5‐year results of Z‐FAST trial (2012) (171)
- Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. (2004) (171)
- Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial (2002) (158)
- Immunological effects of BCG in malignant melanoma: two modes of administration compared. (1972) (137)
- Familial chronic lymphocytic leukemia. (1969) (136)
- Myelofibrosis in chronic granulocytic leukemia. (1971) (123)
- A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project (1977) (119)
- Kaposi's sarcoma: a comparison of classical, endemic, and epidemic forms. (1984) (117)
- Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. (1995) (115)
- Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid (2012) (114)
- Focused microwave phased array thermotherapy for primary breast cancer (2002) (111)
- Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. (1991) (103)
- Pegylated Liposomal Doxorubicin (Doxil®) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience (2002) (99)
- Effects of high dose raloxifene in selected patients with advanced breast carcinoma (2000) (98)
- Hepatitis B virus infection and primary hepatocellular carcinoma. (1977) (97)
- Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer (2007) (92)
- Burkitt's tumor in the United States (1969) (92)
- Kaposi's sarcoma: a new model in the search for viruses associated with human malignancies. (1972) (90)
- Serum alpha-fetoprotein as a biochemical marker for hepatocellular carcinoma. (1972) (90)
- A staging system for hepatocellular carcinoma: Prognostic factors in Ugandan patients (1975) (90)
- Survival after first recurrence of breast cancer. The miami experience (1992) (90)
- Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe? (2012) (89)
- Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. (2004) (81)
- A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States (1977) (80)
- Effect of surgical and chemotherapeutic treatment on alpha‐fetoprotein levels in patients with hepatocellular carcinoma (1976) (79)
- The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. (2004) (76)
- Phase II study of gemcltablne in patients with metastatic breast cancer (1997) (72)
- Clinical Experience with Trastuzumab (Herceptin) (2003) (69)
- A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results. (2009) (69)
- First line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab, humanized anti-HER2 antibody) (2000) (69)
- Pneumocystis carinii pneumonia. (1958) (68)
- Dual HER2-targeted approaches in HER2-positive breast cancer (2011) (64)
- Erratum: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials (Cancer (1998) 83 (1142-1152)) (1999) (63)
- Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy (2013) (60)
- Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study. (1998) (60)
- Toremifene for breast cancer: a review of 20 years of data. (2014) (59)
- Studies on levamisole--induced agranulocytosis. (1980) (55)
- Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer. (2009) (54)
- Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. (2008) (54)
- Monotherapy of metastatic breast cancer: a review of newer agents. (1999) (50)
- Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look. (1972) (44)
- Treatment of kaposi's sarcoma with a combination of actinomycin D and vincristine (1973) (44)
- Immunological Studies in Ugandan Patients with Hepatocellular Carcinoma (1973) (44)
- A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. (1997) (44)
- Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer (2014) (43)
- Treatment of Kaposi's sarcoma by combination of actinomycin‐D, vincristine and imidazole carboxamide (NSC‐45388): Results of a randomized clinical trial (1974) (43)
- Hepatitis-associated antigen and antibody in hepatocellular carcinoma: results of a continuing study. (1972) (42)
- Aspergillus lobar pneumonia. (1969) (41)
- Treatment of Kaposi's sarcoma with actinomycin‐D and cyclophosphamide: Results of a randomtzed cltnical trial (1971) (40)
- Serum alpha‐fetoprotein in 184 ugandan patients with hepatocellular carcinoma. Clinical, laboratory, and histopathologic correlations (1974) (39)
- Adjuvant systemic therapy of primary breast cancer (1988) (37)
- Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature (2015) (37)
- Hepatitis-associated Antigen and Antibody in Uganda: Correlation of Serological Testing with Histopathology (1972) (37)
- A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer (1983) (35)
- Weekly Paclitaxel in Women Age 65 and Above with Metastatic Breast Cancer* (2002) (33)
- Sarcomas and multiple polyposis in a kindred. A genetic variety of hereditary polyposis? (1968) (31)
- Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. (2016) (31)
- Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. (2007) (31)
- Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: A multicenter pilot study (1998) (31)
- Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience (2004) (31)
- Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegf lgrastim clinical trials: a retrospective analysis (2010) (30)
- Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. (1984) (30)
- A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer. (2009) (29)
- Toxoplasma serology in patients with malignant diseases of the reticuloendothelial system (1969) (28)
- International symposium on hepatocellular carcinoma—kampala, uganda (July 1971) (1972) (28)
- Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life. (2005) (28)
- A review of vinorelbine in the treatment of breast cancer. (2001) (27)
- Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. (1999) (27)
- Ectopic production of human chorionic gonadotropin in ugandan patients with hepatocellular carcinoma (1973) (26)
- A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors (2016) (26)
- High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review. (2009) (25)
- Phase II study of oral etoposide for patients with advanced breast cancer (1995) (25)
- Hormonal approaches to breast cancer treatment and prevention: an overview. (1996) (25)
- Serologic diagnosis of active toxoplasmosis complicating malignant diseases. Usefulness of IgM antibodies and gel‐diffusion (1970) (24)
- Needle biopsy in pseudocystis carinii pneumonia. (1969) (24)
- Protocollagen proline hydroxylase in sera of Ugandans with hepatocellular carcinoma. (1972) (24)
- Phase I study and pharmacokinetics of weekly high-dose 13-cis-retinoic acid. (1985) (24)
- Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy. (1978) (24)
- Response to tamoxifen in estrogen receptor‐poor metastatic breast cancer (1987) (22)
- Management of locally advanced breast cancer (stage III): a review. (1984) (22)
- Phase II clinical trials of BCNU )NSC-409962) and bleomycin (NSC-125066) in the treatment of Kaposi's sarcoma. (1973) (22)
- A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer. (2009) (22)
- Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. (2007) (21)
- Trastuzumab plus chemotherapy: convincing survival benefit or not? (2005) (20)
- Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors (2004) (19)
- Clinical trial of high‐dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature (1988) (19)
- Mechanisms of levamisole‐induced granulocytopenia in breast cancer patients (1980) (18)
- Preliminary clinical trials of dichloromethotrexate (NSC-29630) in hepatocellular carcinoma. (1972) (18)
- Burkitt's tumor in the United States. (1969) (17)
- Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study. (2001) (17)
- Ultrastructural survey of primary liver cell carcinomas from Uganda. (1972) (16)
- Defining the Survival Benchmark for Breast Cancer Patients with Systemic Relapse (2015) (16)
- Glutamate dehydrogenase activity related to histopathological grade of hepatocellular carcinoma in man. (1974) (16)
- Effective treatment of Kaposi's sarcoma with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388). (1973) (15)
- Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint? (2008) (15)
- Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study. (2021) (15)
- A phase i study of 4′‐0‐tetrahydropyranyladriamycin: Clinical pharmacology and pharmacokinetics (1990) (15)
- A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer (2014) (14)
- Consensus on Medical Treatment of Metastatic Breast Cancer (2003) (13)
- Efficacy of trastuzumab. (2005) (13)
- Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients (1980) (12)
- Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: a Southeastern Cancer Study Group Trial. (1986) (12)
- JNCCN HER 2 Testing in Breast Cancer : NCCN Task Force Report and Recommendations (2006) (12)
- Mitogen-induced blastogenesis and receptor mobility inhibition by breast cancer serum with elevated orosomucoid (alpha 1-acid glycoprotein) levels. (1982) (12)
- Current status of salvage chemotherapy for refractory advanced breast cancer (1996) (11)
- Management of locally recurrent breast cancer (1993) (11)
- Cyclophosphamide, adriamycin and 5-fluorouracil (CAF) alternating with a cycle-active regimen in metastatic breast cancer: A randomized southeastern cancer study group trial (1981) (11)
- Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). (2020) (10)
- Phase II evaluation of fludarabine in patients with metastatic breast cancer: a Southeastern Cancer Study Group trial. (1986) (10)
- Suppression of experimental allergic encephalomyelitis by NSC 82196, a new imidazole carboxamide derivative. (1969) (10)
- Immunologic studies in American patients with Burkitt-like lymphoma. (1967) (10)
- Treatment of advanced adenocarcinoma of the kidney with ICRF-187: a Southeastern Cancer Study Group Trial. (1986) (10)
- P1-07-02: Discordance between Central and Local Laboratory HER2 Testing from a Large HER2−Negative Population in VIRGO, a Metastatic Breast Cancer Registry. (2011) (9)
- Reported Bone Pain in Cancer Patients Receiving Chemotherapy in Pegfilgrastim Clinical Trials: A Retrospective Analysis. (2009) (9)
- Dopa and 5-S-cysteinyldopa in malignant melanoma in Ugandan Africans. (1974) (9)
- Evaluation of human chorionic gonadotropin and alpha fetoprotein in benign and malignant testicular disorders. (1978) (9)
- The role of growth factor support following neutropenic events in early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001. (2004) (8)
- Update on the current use of hormonals as therapy in advanced breast cancer (2003) (8)
- Response to oophorectomy after tamoxifen failure in a premenopausal patient. (1982) (8)
- A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer (1985) (8)
- Evaluation of reported bone pain in patients (pts) receiving chemotherapy in pegfilgrastim clinical trials. (2016) (7)
- Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer (2010) (7)
- Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1). (2009) (7)
- Phase I trial of misonidazole (NSC#261037) plus cyclophosphamide in solid tumors. (1985) (7)
- Management of Kaposi's sarcoma. Chemotherapy I. (1981) (7)
- Fluorescence in situ hybridization (FISH) may accurately select patients likely to benefit from herceptin monotherapy (2001) (6)
- Rivanol precipitation technique for the detection of alpha-feto-protein. (1972) (6)
- Treatment of experimental allergic encephalomyelitis in the rabbit. (1972) (6)
- Management of Kaposi’s Sarcoma (1981) (6)
- Relationship of estrogen receptor (ER) status to clinical benefit in clinical trials of herceptin (2001) (6)
- Response to tamoxifen in estrogen receptor-poor metastatic breast cancer. (1987) (5)
- Phase I trial of dianhydrogalactitol administered Iv in a weekly schedule. (1976) (5)
- Adjuvant Docetaxel plus Doxorubicin and Cyclophosphamide for Node-Positive Breast Cancer (2005) (5)
- Docetaxel-based regimen (TAC) improves DFS and OS over FAC in node positive early breast cancer patients: efficacy, safety and quality of life at 55 month follow-up (2004) (5)
- Enhanced Suppression of Experimental Allergic Encephalomyelitis by Combination Chemotherapy with Duazomycin-A and 6-Mercaptopurine∗ (1969) (5)
- Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer. (2005) (5)
- Randomized double‐blind phase 2 trial of 3 doses of TAS‐108 in patients with advanced or metastatic postmenopausal breast cancer (2012) (5)
- Acupuncture for the management of hot flashes in women with early stage breast cancer treated with tamoxifen or an aromatase inhibitor: A pilot study of efficacy, safety and feasibility (2005) (5)
- Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy. (1978) (4)
- BCIRG 001 molecular analysis: Identification of prognostic factors in patients (pts) receiving adjuvant therapy for node- positive (N+) breast cancer (BC) (2007) (4)
- Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer (2019) (4)
- A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer. (2015) (4)
- Clinical trials of combination chemotherapy with BCNU and vincristine in the treatment of malignant melanoma in Uganda (1973) (4)
- Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY). (1980) (4)
- Phase II trial of recombinant Beta (IFN-Betaser) interferon in the treatment of metastatic breast cancer (1988) (4)
- Blood coagulation and fibrinolysis in Ugandan patients with cirrhosis and hepatocellular carcinoma. (1974) (3)
- Updated results of a multicenter phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC). (2005) (3)
- Safety and efficacy of single-agent adjuvant trastuzumab in older women with early-stage breast cancer. (2020) (3)
- 351 Two randomised trials establishing efficacy and tolerability of arimidex (ZD1033) in the treatment of postmenopausal women with advanced breast cancer (PABC) (1995) (3)
- Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients (2019) (3)
- Phase II trial of trastuzumab and paclitaxel or docetaxel administered every 3 weeks to patients receiving a first treatment for HER2+ metastatic breast cancer. (2004) (3)
- Liver celldysplasia: apremalignant condition (1973) (3)
- Abstract PD8-10: Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER+/AR+ breast cancer - final results from an international Phase 2 randomized study (2021) (3)
- Estrogen receptor status in the Herceptin (trastuzumab) clinical trials: Incidence and relation to clinical benefit (2001) (3)
- Correlation between estrogen receptors and response to nonhormonal chemotherapy in metastatic breast cancer (1981) (3)
- RATIONALE FOR TRIALS STUDYING PEGYLATED LIPOSOMAL DOXORUBICIN IN METASTATIC BREAST CANCER (1997) (3)
- Phase II study of alternating cytoreductive and cycle-active combination chemotherapy for metastatic breast cancer. (1979) (2)
- Phase II trial of docetaxel and Herceptin (R) as first- or second-line chemotherapy for women with metastatic breast cancer whose tumours overexpress HER2 (1999) (2)
- Comparison of the incidence of peripheral neuropathy (PN) with eribulin versus ixabepilone (IXA) in metastatic breast cancer (MBC) patients: A randomized phase II study. (2012) (2)
- Complete response in metastatic breast cancer (1986) (2)
- Trastuzumab Monotherapy (2004) (2)
- Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer (1984) (2)
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease (2023) (2)
- Sequential versus concomitant chemo-hormonal therapy in breast cancer (1982) (2)
- Phase I study of misonidazole and cyclophosphamide in solid tumors (1982) (2)
- P5-19-02: Comparison of the Incidence of Peripheral Neuropathy with Eribulin Mesylate Versus Ixabepilone in Metastatic Breast Cancer Patients: A Randomized Phase II Study. (2011) (2)
- Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis. (2013) (2)
- Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC) (2017) (2)
- Reported Bone Pain in Patients with Breast Cancer Receiving Taxane-Based Chemotherapy in Clinical Trials of Pegfilgrastim.: (2009) (2)
- High dose estrogen as a salvage hormonal strategy for highly refractory metastatic breast cancer (MBC): “back to the future.”. (2009) (2)
- Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: The Southeastern Cancer Study Group experience (1983) (1)
- Safety of zoledronic acid in patients who have previously received bisphosphonate therapy. (2004) (1)
- Estrogen priming before progestin therapy in advanced breast cancer (1990) (1)
- Phase I clinical trial of weekly intravenous ICRF-187 (NSC 169780): A Southeastern Cancer Study Group trial (1981) (1)
- Liver cell dysplasia: a premalignant condition. (1973) (1)
- Levamisole granulocytopenia in patients receiving an adjuvant chemoimmunotherapy program after surgery for breast carcinoma with axillary lymph node involvement. (1978) (1)
- Recent trends in breast cancer treatment. (1978) (1)
- Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial. (1988) (1)
- A Phase I Clinical Trial of a Combination of Mitoxantrone, 5‐Fluorouracil, and High‐Dose Leucovorin Given on a Day 1 and Day 8 Schedule to Patients with Metastatic Breast Cancer (1994) (1)
- Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature (2022) (1)
- High dose oral medroxy-progesterone acetate (HDO-MPA) for advanced breast cancer (BC) (1982) (1)
- Systemic therapy of breast cancer--1985. (1985) (1)
- The effect of obesity on prognosis in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathologic subtypes. (2013) (1)
- A randomized, phase II trial of AEZS-108 in chemotherapy refractory triple-negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer. (2013) (1)
- A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer (2011) (1)
- Maximizing differences in the concanavalin A-induced blastogenic responses of lymphocytes from breast cancer patients and controls by the use of alpha-methyl-D-mannoside. (1982) (1)
- Multicenter P hase I I T rial o f W eekly P aclitaxel i n W omen With M etastatic B reast C ancer (2001) (0)
- Reply to R.S. Mehta et al (2009) (0)
- Sequential (SEQ) versus combination (COMB) hormonal and chemotherapy in post menopausal patients with metastatic breast cancer (1977) (0)
- Reply to L.C. Panasci (2009) (0)
- Systemic cancer therapy: four decades of progress and some personal perspectives. (1990) (0)
- Highlights in metastatic breast cancer from the 2011 San Antonio Breast Cancer Symposium (SABCS). (2012) (0)
- Modal Hyperploidy in Human Neoplasia (1974) (0)
- Abstract OT2-3-11: Tivozanib in combination with paclitaxel vs placebo with paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer (2012) (0)
- Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial. (1987) (0)
- Decetaxel incombination rhuMAb hr2 for the treatment of cancers. (2000) (0)
- Phase I trial of 1,2: 5,6 dianhydrogalactitol (DAGA) (NSC 132-313) administered in a weekly schedule (1976) (0)
- Capecitabine plus docetaxel (XT): A first line, phase II clinical trial in metastatic breast cancer. (2006) (0)
- Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma (1988) (0)
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. (2023) (0)
- Abstract P1-11-05: Phase 2 Study of Neoadjuvant Treatment with Cellular Redox Modulator NOV-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) in Patients with Stage II-III HER-2 (-) Breast Cancer (2010) (0)
- 100P Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study (2021) (0)
- A clinical dilemma : isolated breast cancer recurrence and dose intensive chemotherapeutic strategies (1991) (0)
- Commentary (Vogel): Trastuzumab in Breast Cancer (2004) (0)
- Cisplatin/Epinephrine Injectable Gel for Intratumoral Therapy of Accessible Solid Tumors Including Head and Neck Squamous Cell Carcinoma (1996) (0)
- lighttheneedforresearchdesignedtobetterdefinethecon- textinwhichfishoilmaybenefitpatientswithcoronaryartery disease. (2017) (0)
- When Can a Salvage Therapy (T-DM1) Take the Lead? (2016) (0)
- Efficacy a nd S afety o f T rastuzumab a s a S ingle A gent i n First-Line T reatment o f HER2 -Overexpressing M etastatic Breast C ancer (2011) (0)
- Vinorelbine plus capecitabine in a heavily pretreated HER2 negative metastatic breast cancer patient population: MCEPASTEBIN. (2018) (0)
- Systemic therapy for breast cancer: changing trends, 1980. (1980) (0)
- Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy. (2022) (0)
- Abstract P1-12-03: Low-dose capecitabine monotherapy in HER-2 negative metastatic breast cancer: a retrospective study. (2012) (0)
- Alternating cytoreductive and cycle-active combination chemotherapy in metastatic breast cancer (MBC) (1978) (0)
- Letter: Modal hyperploidy in human neoplasia. (1974) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Charles Le. Vogel?
Charles Le. Vogel is affiliated with the following schools: